Anticipation for hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma  

作　　者：Grigorios Christodoulidis Dimitra Bartzi Konstantinos E Koumarelas 

机构地区：[1]Department of General Surgery,University Hospital of Larissa,Larissa 41335,Greece [2]Department of Oncology,The 251 Airforce General Hospital,Athens 11525,Greece [3]Department of Emergency Medicine,General Hospital of Larissa,Larissa 41221,Greece

出　　处：《World Journal of Gastrointestinal Oncology》2025年第2期304-310,共7页世界胃肠肿瘤学杂志(英文)

摘　　要：Hepatic arterial infusion chemotherapy (HAIC) is an advanced targeted therapeuticapproach for hepatocellular carcinoma (HCC), the most common type ofprimary liver cancer. HAIC has demonstrated significant potential in managingadvanced HCC, particularly in regions with high prevalence rates. Despite itspromise, several challenges and areas for future research remain. Clinical studieshave substantiated the efficacy of HAIC in enhancing survival outcomes forpatients with advanced hepatic carcinoma. Notably, combination therapiesinvolving immune checkpoint inhibitors, such as lenvatinib and programmeddeath-1 inhibitors, have shown substantial improvements in median overallsurvival and progression-free survival compared to systemic chemotherapy.These combination therapies have also exhibited superior response rates anddisease control, with manageable and often less severe adverse events relative tosystemic treatments. This article is based on the review by Zhou et al and aims todiscuss the current status and future directions in the treatment of HCC, emphasizingthe role of HAIC and its integration with novel therapeutic agents.

关 键 词：Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Targeted therapy CHALLENGES SAFETY Advantages 

分 类 号：R735.7[医药卫生—肿瘤]